Residual reversibility in COPD subjects treated by long acting bronchodilatators Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018
Respiratory muscle strength and perception of dyspnea during bronchodilator response test in patients with stable COPD Source: Annual Congress 2008 - Respiratory muscles in disease Year: 2008
Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response Source: Eur Respir J 2006; 28: Suppl. 50, 428s Year: 2006
Effects of supplemental oxygen and high-dose inhaled bronchodilator therapy in exercise performance and dyspnoea in patients with stable COPD Source: Annual Congress 2004 - Exercise and systemic effects in COPD Year: 2004
Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Improvement in airflow obstruction with inhaled bronchodilators influences the pattern of abdominal muscle recruitment during exercise in COPD Source: Annual Congress 2010 - Thoracic dynamics and dyspnoea on exercise Year: 2010
Assessment of respiratory muscle strength in asmathic children: Influence of inhaled corticosteroids Source: Annual Congress 2010 - Advances in lung function from infancy to adolescence Year: 2010
Inhaled vilanterol trifenatate/fluticasone furoate increases maximum diaphragm contraction in severe COPD Source: International Congress 2014 – Clinical physiology and respiratory muscles Year: 2014
Bronchodilator reversibility and short-term inhaled corticosteroid response in Japanese patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004
Inhaled anticholinergics affect the heart rate recovery in stable COPD patients Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD Source: Eur Respir J 2016; 47: 651-654 Year: 2016
Acute and chronic effects of inhaled bronchodilators in patients with 'irreversible' COPD at rest and during exercise Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
Acute bronchodilator responsiveness in a global respiratory trial (UPLIFT) following maximal inhaled bronchodilators Source: Eur Respir J 2005; 26: Suppl. 49, 716s Year: 2005
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014
Evaluation of respiratory muscles‘ function in COPD patients treated with tiotropium Source: Eur Respir J 2005; 26: Suppl. 49, 291s Year: 2005
Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017
Inhaled beta-agonist does not modify sympathetic activity in patients with COPD Source: International Congress 2014 – Multidimensional analysis of respiratory problems Year: 2014
Determinants of long acting bronchodilator adherence in UK COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006